OPKO Health, Inc. (OPK) AI Stock Analysis

OPKO Health, Inc. is a diversified healthcare company operating diagnostics and pharmaceutical businesses across the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. Its Diagnostics segment is anchored by BioReference Laboratories, which offers laboratory testing services including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, correctional healthcare, and 4Kscore prostate cancer testing. Its Pharmaceuticals segment markets Rayaldee for secondary hyperparathyroidism and develops therapies including OPK88004, OPK88003 for type 2 diabetes and obesity, and hGH-CTP in collaboration with Pfizer, Inc. The company also produces and distributes various pharmaceutical, nutraceutical, veterinary, and ophthalmic products.

Revenue contracted steadily from $1.77B in FY2021 to $1.00B in FY2022, $863.5M in FY2023, $713.1M in FY2024, and $606.9M in FY2025, generating a 5-year revenue CAGR of -15.8%. Operating margin declined from 1.1% in FY2021 to -36.1% in FY2025, while gross margin fell from 32.8% to 21.1% over the same timeframe. Annual net losses widened to -$225.7M in FY2025, corresponding to an EPS of -$0.18, compared to -$53.2M in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $587.9M with a profit margin of -12.4%. In the latest quarter, revenue grew 4.3% year-over-year, while quarterly earnings declined 12.6%.

As of June 30, 2026, OPKO Health held $300.8M in cash and short-term investments against total debt of $392.3M, resulting in net debt of $91.5M. The company reported total assets of $1.83B, shareholders' equity of $1.18B, a current ratio of 3.35, and a debt-to-equity ratio of 0.33. Operating cash flow in FY2025 was -$178.5M, and free cash flow was -$190.8M. Cash outlays in FY2025 included capital expenditures of $12.3M and share buybacks of $47.0M.

OPKO Health trades at a forward P/E of 53.8x, compared to 17.3x for the median of its US-listed Healthcare peers. Its enterprise value of $1.37B equates to an EV/EBITDA multiple of 24.9x, above the peer median of 12.0x, while its price-to-sales ratio of 1.9x sits below the peer median of 4.1x. Over the past year, OPKO Health shares gained 2.0%, trailing the S&P 500 (SPY) return of 16.8%. Over a 5-year span, the stock fell 58.9%, compared to an 83.0% gain for SPY.

Wall Street coverage consists of 2 Strong Buy, 2 Buy, and 2 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target of $4.15 implies an upside of 171.2% from the last close of $1.53. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.21 on revenue of $569.9M. For the next fiscal year, 3 analysts project revenue of $495.1M and EPS of -$0.34. The company beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of OPKO Health, Inc. (OPK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OPK income statement, OPK balance sheet, OPK key metrics, OPK analyst forecast, OPK chart. See the OPK stock overview for the latest quote and news.